Budair 0.25Mg/Ml, Budair 0.5Mg/Ml 0.25 mg, 0.5 mg NEBULISER SUSPENSION
PDF Leaflet Revision Date: 6 September 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Management of asthma and acute laryngotracheobronchitis in children.
Dosage (summary)
Adults: 0.5-1 mg twice daily; Children: 0.25-1 mg twice daily based on previous therapy.
Special Populations
- Children under 12 months
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established; inhaled corticosteroids preferred.
Key Drug Interactions
- CYP3A inhibitors (e.g., ketoconazole, itraconazole)
Contraindications
- Hypersensitivity to budesonide
- Lung tuberculosis
- Fungal and viral infections in airways
Common side effects
- Oropharyngeal candidiasis
- Coughing
- Hoarseness
- Throat irritation
Counselling Points
- Rinse mouth after use to prevent thrush
- Monitor for signs of adrenal insufficiency
- Avoid use in acute asthma episodes
Serious warnings
- Risk of adrenal insufficiency
- Potential for pneumonia in COPD patients
- Growth retardation in children
Important Disclaimer
The Budair 0.25Mg/Ml, Budair 0.5Mg/Ml 0.25 mg, 0.5 mg NEBULISER SUSPENSION professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
